<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>UEA MED Genomics Pipelines</title>
    <link>/</link>
      <atom:link href="/index.xml" rel="self" type="application/rss+xml" />
    <description>UEA MED Genomics Pipelines</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><lastBuildDate>Mon, 07 Sep 2020 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/images/logo_hu5089cb47d23b8d50047ff1ec9a8ad388_44564_300x300_fit_lanczos_2.png</url>
      <title>UEA MED Genomics Pipelines</title>
      <link>/</link>
    </image>
    
    <item>
      <title>Germline variant caller</title>
      <link>/publication/germline_variant/</link>
      <pubDate>Mon, 07 Sep 2020 00:00:00 +0000</pubDate>
      <guid>/publication/germline_variant/</guid>
      <description>&lt;img src=&#34;brca.png&#34; alt=&#34;drawing&#34; style=&#34;width:500px;&#34;/&gt;
&lt;p&gt;&lt;em&gt;Figure 1 - An example of inheritance of the genetically dominant BRCA mutation.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;A germline mutation is characterised by a change in bases that are occur within the gamete cells, thus resulting in these mutations to be present in every somatic cell of an individual. Given that germline mutagenesis is a fundamental biological process driving heritable genetic variation, identifying germline variant which attribute to a particular disease can be a challenging task. We have developed a germline variant discovery pipeline that utilises two independent variant callers; GATK Haplotype caller and Freebayes (figure 2). This pipeline accepts both exome and whole genome sequencing data, in addition to an optional pedigree (PED) file to allow overlap between disease affected/unaffected family members.&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;&lt;img src=&#34;flowchart.png&#34; alt=&#34;Figure 2 - flowchart depicting UEA MED genomics germline. pipeline&#34;&gt;&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Figure 2 - A flowchart depicting UEA MED genomics QC and germline pipeline.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;The GATK module includes all the recommended tools described from the 
&lt;a href=&#34;https://gatk.broadinstitute.org/hc/en-us/articles/360035535932-Germline-short-variant-discovery-SNPs-Indels-&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Germline short variant discovery (SNPs + Indels workflow)&lt;/a&gt;. This module automates 11 processes including recalibration against known common variants, variant calling (HaplotypeCaller), convolutional neural network variant scoring and filtering  to produce a list of high quality variants. In contrast, our Freebayes module utilises a bayesian  approach which then filters variants based on quality scores and depth (&lt;a href=&#34;https://github.com/ekg/freebayes)&#34;&gt;https://github.com/ekg/freebayes)&lt;/a&gt;.&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;
  
  &lt;script src=&#34;https://cdn.plot.ly/plotly-latest.min.js&#34;&gt;&lt;/script&gt;




&lt;div id=&#34;plotly2.json&#34; class=&#34;plotly&#34; style=&#34;height:600px&#34;&gt;&lt;/div&gt;
&lt;script&gt;
Plotly.d3.json(&#34;plotly2.json&#34;, function(err, fig) {
    Plotly.plot(&#39;plotly2.json&#39;, fig.data, fig.layout, {responsive: true});
});
&lt;/script&gt;

&lt;em&gt;Figure 2 - an exmaple of SIFT prediction of deleteriousness for variants. Part of the germline variant pipeline.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;Next, variants called by GATK haplotype caller and Freebayes are overlapped and annotated using variant effect predictor (VEP). Common variants are filtered using the GnomAD database for sequencing data using user define cut off values; SIFT and PolyPhen are used to predict the deleteriousness of variant (figure 2). A user-friendly html report is created providing interactive tables and plots allowing users to interrogate the new rare-variant results - an example of this report can be found 
&lt;a href=&#34;https://uea-med-pipelines.netlify.app/project/external_project/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;here&lt;/a&gt; in the Cholesteatoma project we have recently processed (as of Sept 2020).&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Somatic variant caller</title>
      <link>/publication/somatic_variant/</link>
      <pubDate>Mon, 07 Sep 2020 00:00:00 +0000</pubDate>
      <guid>/publication/somatic_variant/</guid>
      <description>&lt;p&gt;&lt;img src=&#34;signature.png&#34; alt=&#34;Figure - mutational signature analysis from Tumoroid cancer project&#34;&gt;&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;After samples have passed QC, tumor-normal matched samples can be analysed using our somatic variant pipeline - both exome and whole genome sequencing (WGS) is supported with these pipelines. This pipeline utilises 2 independent variant callers from Sanger and GATK.&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;The Sanger pipelines cgpWXS and cgpWGS were designed for exome and WGS, respectively (&lt;a href=&#34;https://github.com/cancerit)&#34;&gt;https://github.com/cancerit)&lt;/a&gt;. Both Sanger pipelines utilise CAVeMAN and Pindel to call single base substitutions (SBSs) and insertions-deletions (indels) which are annotated by VAGrENT. CgpWGS also includes BRASS and ascatNgs for breakpoint and copy number analysis. Both tools identify high quality variants that are used downstream for further analysis.&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;The GATK pipeline was developed in-house and include all the reccomennded tools described in the the  
&lt;a href=&#34;https://gatk.broadinstitute.org/hc/en-us/articles/360035889791--How-to-Call-somatic-mutations-using-GATK4-Mutect2-Deprecated-&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;mutect2 GATK workflow&lt;/a&gt;. This pipeline automates 10 processes including recalibration against known common variants, variant calling (mutect2), contamination calculation and filtering variants to produce a list of high quality variants.&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;The final part of the somatic variant pipeline creates an overlap between the variants found in both Sanger and GATK variant callers. A html report is created from the results that includes annotated variants significantly different between normal and tumor samples, variant class summary (E.g. nosense, stop codon, etc) across samples, cancer drug prediction and variant allele frequencies - an example of this is shown in the colorectal cancer tumoroid project [here](put inthe hhtps when ready)&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Variant QC Pipeline</title>
      <link>/publication/qc/</link>
      <pubDate>Mon, 07 Sep 2020 00:00:00 +0000</pubDate>
      <guid>/publication/qc/</guid>
      <description>&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;&lt;img src=&#34;fastqc.jpg&#34; alt=&#34;&#34;&gt;&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;Quality control (QC) is an essential step in any NGS experiment, there a number of sequencing artefacts such as read errors, primer/adapter contamination, PCR/optical read duplication are quite common. Failure to remove such artefacts can greatly and negatively impact upon downstream analyses and produce errouneous conclusions. The majority of these downstream analyses do not perform filtering steps or provide tools for QC, therefore these sequencing artefacts are required to be filtered out to prevent inaccurate results.&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;&lt;img src=&#34;QC_pipeline.png&#34; alt=&#34;figure 1 - QC pipeline flowchart &#34;&gt;&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Figure 1 - QC pipeline flowchart.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;We have developed pipelines that include the all the essential QC tools for both RNA and DNA (variant exome and WGS) sequencing experiments - summarised in figure 1. Irrespective of sample type, samples are first trimmed using TrimGalore, analysed by FastQC and aligned (cgpMAP and HISAT2 for DNA and RNA, respectively). The picard toolkit suite is also used to remove PCR and optical duplicates, give read insert sizes and alignment statistics.&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;Additional tools have been included to estimate the levels of contamination (verifyBAMID), relatedness scores and ancestry estimation in DNA-seq samples (Somalier) - shown in figure 2. These analsyes allow the identification of samples that may have been mislabelled, contaminated or degraded thus preventing errouneous result interepretation.&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;Once all analyses have been performed, multiQC is used to create QC plots reporting results in an easy and digestible format. An example of a multiQC report is 
&lt;a href=&#34;https://multiqc.info/examples/wgs/multiqc_report.html#qualimap&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;here&lt;/a&gt;. If samples pass QC, they will progress onto their chosen downstream analysis - such as the germline or somatic variant discovery pipelines.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Cholesteatoma - rare variant discovery</title>
      <link>/project/external_project/</link>
      <pubDate>Tue, 30 Jul 2019 00:00:00 +0000</pubDate>
      <guid>/project/external_project/</guid>
      <description>&lt;h2 id=&#34;introduction&#34;&gt;Introduction&lt;/h2&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;Cholesteatoma is a rare disorder that is characterised by a large mass of keratinising epithelium in the middle ear. The aetiology of the disease is large unknown, therefore the UEA MED cholesteatoma genetics team utilised whole exome sequencing to identify germline mutants that may explain these outcome. We utilised our germline variant discovery pipeline (as described in the pipeline 
&lt;a href=&#34;https://uea-med-pipelines.netlify.app/publication/germline_variant/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;section&lt;/a&gt;) to analyse these samples. Below shows an example of some of the analyses included in the report generated for this project:&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;iframe
  src=&#34;chole_mock_v0.1.html&#34;
  style=&#34;width:100%; height:600px;&#34;
&gt;&lt;/iframe&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Colorectal cancer tumoroid project</title>
      <link>/project/internal_project/</link>
      <pubDate>Tue, 30 Jul 2019 00:00:00 +0000</pubDate>
      <guid>/project/internal_project/</guid>
      <description>&lt;h2 id=&#34;introduction&#34;&gt;Introduction&lt;/h2&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;Dr Mark Williams and his team are interested in the genetics of colorectal cancer, utilising complex 3D culturing techniques to identify potentially novel and effective treatment strategies. Dr Williams provided us with high quality DNA-exome sequence from patient matched tumoroid and organoid cultures to be processed by our somatic variant discovery pipeline. As described in our somatic pipelines 
&lt;a href=&#34;https://uea-med-pipelines.netlify.app/publication/somatic_variant/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;section&lt;/a&gt;, the sanger cgpWXS and GATK mutect2 tools were utilised to identify high confidence variants specific to the tumor samples. Below shows an example of some summary results produced by this project:&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
&lt;iframe
  src=&#34;tumoroid_mock_v0.1.html&#34;
  style=&#34;width:100%; height:600px;&#34;
&gt;&lt;/iframe&gt;
&lt;p&gt;&lt;br /&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Quality Control Pipeline</title>
      <link>/post/qc/</link>
      <pubDate>Tue, 30 Jul 2019 00:00:00 +0000</pubDate>
      <guid>/post/qc/</guid>
      <description>&lt;h2 id=&#34;introduction&#34;&gt;Introduction&lt;/h2&gt;
&lt;p&gt;\&lt;/p&gt;
&lt;p&gt;\&lt;/p&gt;
&lt;p&gt;Dr Mark Williams provided us with high quality DNA-exome sequence from 3D culture tumoroid and organoid cultures to be processed by our somatic variant discovery pipeline. For this project, we&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Privacy Policy</title>
      <link>/privacy/</link>
      <pubDate>Thu, 28 Jun 2018 00:00:00 +0100</pubDate>
      <guid>/privacy/</guid>
      <description>&lt;p&gt;Add your privacy policy here and set &lt;code&gt;draft: false&lt;/code&gt; to publish it. Otherwise, delete this file if you don&amp;rsquo;t need it.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Terms</title>
      <link>/terms/</link>
      <pubDate>Thu, 28 Jun 2018 00:00:00 +0100</pubDate>
      <guid>/terms/</guid>
      <description>&lt;p&gt;Add your terms here and set &lt;code&gt;draft: false&lt;/code&gt; to publish it. Otherwise, delete this file if you don&amp;rsquo;t need it.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
